← Leaderboards
Olga Rafikova
Augusta University
$5,082,063
Attributed
$5,082,063
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,082,063 · 4
By mechanism
R01$4,593,157 · 2
R41$373,684 · 1
F32$115,222 · 1
Top collaborators
No co-investigators on record.
Most similar at Augusta University
Same institution · by research overlap
- Scott A Barman$6,157,524
- David J Fulton$11,867,025
- Stephen Haigh$123,234
- Eric J Belin De Chantemele$9,748,233
- Laszlo Kovacs$760,760
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeLungRattusSignal TransductionMediatingPreventEventPulmonary Arterial HypertensionRight Ventricular StructurePhenotypeMortalityAttenuatedMolecularBasePrimary Pulmonary HypertensionIn VivoApoptosisBindingIn VitroPulmonary HypertensionOxidationReceptorBlood VesselsMetabolism
Grant awards (13)
Mitochondrial dysfunction in pulmonary hypertension$676,676
R01 · FY2025 · HL · contact PI
Mitochondrial dysfunction in pulmonary hypertension$664,270
R01 · FY2024 · HL · contact PI
Mitochondrial dysfunction in pulmonary hypertension$624,575
R01 · FY2023 · HL · contact PI
Mitochondrial Dysfunction in Pulmonary Hypertension$35,175
R01 · FY2023 · HL · contact PI
Mitochondrial Dysfunction in Pulmonary Hypertension$673,711
R01 · FY2022 · HL · contact PI
Profiling circulating metabolites for the diagnosis of pulmonary hypertension$373,684
R41 · FY2022 · HL · contact PI
HMGBG1 and Gender Difference in Pulmonary Arterial Hypertension$383,750
R01 · FY2020 · HL · contact PI
HMGBG1 and Gender Difference in Pulmonary Arterial Hypertension$383,750
R01 · FY2019 · HL · contact PI
HMGBG1 and Gender Difference in Pulmonary Arterial Hypertension$383,750
R01 · FY2018 · HL · contact PI
HMGBG1 and Gender Difference in Pulmonary Arterial Hypertension$383,750
R01 · FY2017 · HL · contact PI
HMGBG1 and Gender Difference in Pulmonary Arterial Hypertension$383,750
R01 · FY2016 · HL · contact PI
Endothelin and EGFR Activation in Pulmonary Hypertension$59,432
F32 · FY2012 · HL · contact PI
Endothelin and EGFR Activation in Pulmonary Hypertension$55,790
F32 · FY2010 · HL · contact PI